Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: A review

AIDS Patient Care and STDs

Volumn 26, Issue 10, 2012, Pages 568-581

  Van Maarseveen, Erik M ^a   Rogers, Christin C ^b   Trofe Clark, Jennifer ^c,d   Van Zuilen, Arjan D ^a   Mudrikova, Tania ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; LAMIVUDINE; MARAVIROC; MYCOPHENOLIC ACID; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RAPAMYCIN; RITONAVIR; STAVUDINE; TACROLIMUS; TENOFOVIR; UNINDEXED DRUG; ZIDOVUDINE;

ARTICLE; DRUG ELIMINATION; DRUG METABOLISM; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MIXED INFECTION; ORGAN TRANSPLANTATION; POSTOPERATIVE CARE;

DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV FUSION INHIBITORS; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE;

EID: 84867032501     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2012.0169     Document Type: Article

References (82)

1. Fine DM, Perazella MA, Lucas GM, Atta MG. Renal disease in patients with HIV infection: Epidemiology, pathogenesis and management. Drugs 2008;68:963-980. (Pubitemid 351652924)
2. Yoon SC, Hurst FP, Jindal RM, et al. Neff RT, Agodoa LY, Kimmel PL, Abbott KC. Trends in renal transplantation in patients with human immunodeficiency virus infection: An analysis of the United States renal data system. Transplantation. 2011;91:864-868.
3. Schwartz EJ, Szczech LA, Ross MJ, Klotman ME, Winston JA, Klotman PE. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Ne-phrol 2005;16:2412-2420. (Pubitemid 41725059)
4. Sherman KE Thomas DL, Chung RT. Human immunodeficiency virus and liver disease forum 2010: Conference proceedings. Hepatology 2011;54:2245-2253.
5. Stock PG, Barin B, Murphy B, et al. Outcome of kidney transplantation in HIV-infected recipients. N Engl J Med 2010;363:2004-2014.
6. Touzot M, Pillebout E, Matignon M, et al. Renal transplantation in HIV-infected patients: The Paris experience. Am J Transplant 2010;10:2263-2269.
7. Jain AB, Venkataramanan R, Eghtesad B, et al. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacroli-mus blood concentration in liver transplant patients. Liver Transpl 2003;9:954-960. (Pubitemid 37098844)
8. Tseng A, Foisy M. Important drug-drug interactions in HIV-infected persons on antiretroviral therapy: An update on new interactions between HIV and non-HIV drugs. Curr Infect Dis Rep 2012;14:67-82.
9. Trullas JC, Cofan F, Tuset M, et al. Renal transplantation in HIV-infected patients: 2010 update. Kidney Int 2011;79: 825-842.
10. Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplantation in HCV-HIV coinfected recipients. Liver Transpl (in press).
11. Cooper C, Kanters S, Klein M, et al. Liver transplant outcomes in HIV-infected patients: A systematic review and meta-analysis with synthetic cohort. AIDS 2011;25:777-786.
12. Beatty G. HIV-related predictors and outcomes in 275 liver and/or kidney transplant recipients [Abstrac MOAB0105]. 6th IAS Conference 2011. Rome: July 17-20, 2011.
13. Miro JM, Ricart MJ, Trullas JC, et al. Simultaneous pancreas-kidney transplantation in HIV-infected patients: A case report and literature review. Transplant Proc 2010;42:3887-3891.
14. Bertani A, Grossi P, Vitulo P, et al. Successful lung transplantation in an HIV-and HBV-positive patient with cystic fibrosis. Am J Transplant 2009;9:2190-2196.
15. Grossi PA, Righi E, Gasperina DD, et al. Report of four simultaneous pancreas-kidney transplants in HIV-positive recipients with favorable outcomes. Am J Transplant (in press).
16. Allers K, Hütter G, Hofmann J, et al. Evidence for the cure of HIV infection by CCR5D32/D32 stem cell transplantation. Blood 2011;117:2791-2799.
17. Kuball J. Towards the next generation in transplantation: HIV positive patients. 10th International cord blood symposium. San Francisco, CA: June 7-9, 2012, Abstract Booklet page 11.
18. Abbott KC, Swanson SJ, Agodoa LY, Kimmel PL. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol 2004;15: 1633-1639. (Pubitemid 38679689)
19. Chadban SJ Barraclough KA, Campbell SB, et al. KHA-CARI guideline: KHA-CARI adaptation of the KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Nephrology (Carlton) 2012;17:204-214.
20. Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1-and 3-year outcomes. Am J Transplant 2008;8:355-365.
21. Calabrese LH, Lederman MM, Spritzler J, et al. Placebo-controlled trial of cyclosporin-A in HIV-1 disease: Implications for solid organ transplantation. J Acquir Immune Defic Syndr 2002;29:356-362. (Pubitemid 34288888)
22. Rizzardi GP, Harari A, Capiluppi B, et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002;109:681-688. (Pubitemid 34204847)
23. Braaten D Luban J. Cyclophilin A regulates HIV-1 infectiv-ity, as demonstrated by gene targeting in human T cells. EMBO J 2001;20:1300-1309. (Pubitemid 32233970)
24. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29:404-430. (Pubitemid 26004179)
25. Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: An overview. Liver Transpl 2001;7:473-484.
26. Sankatsing SU, Hoggard PG, Huitema AD, et al. Effect of mycophenolate mofetil on the pharmacokinetics of anti-retroviral drugs and on intracellular nucleoside triphosphate pools. Clin Pharmacokinet 2004;43:823-832. (Pubitemid 39382222)
27. Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR. Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals. J Acquir Immune Defic Syndr 2008;48:561-566.
28. HHS. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents 2011. www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (Last accessed on February 3, 2012).
29. Coull JJ, Turner D, Melby T, Betts MR, Lanier R, Margolis DM. A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr 2001;26:423-434. (Pubitemid 32489020)
30. Margolis DM, Kewn S, Coull JJ, et al. The addition of my-cophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deox-yguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr 2002;31:45-49.
31. Millán O, Brunet M, Martorell J, et al. Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir. Clin Pharmacokinet 2005;44:525-538. (Pubitemid 40733737)
32. Antoniades C, Macdonald C, Knisely A, Taylor C, Norris S. Mitochondrial toxicity associated with HAART following liver transplantation in an HIV-infected recipient. Liver Transpl 2004;10:5.
33. Sankatsing SU, Jurriaans S, van Swieten P, et al. Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients. AIDS 2004;18: 1925-1931. (Pubitemid 39313208)
34. Frassetto L, Baluom M, Jacobsen W, et al. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation 2005;80:13-17. (Pubitemid 40980889)
35. Tan HP, Kaczorowski DJ, Basu A, et al. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: A single center preliminary experience. Transplantation. 2004; 78:1683-1688. (Pubitemid 39648444)
36. Teicher E, Vincent I, Bonhomme-Faivre L, et al. Effect of highly active antiretroviral therapy on tacrolimus pharma-cokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Phar-macokinet 2007;46:941-952. (Pubitemid 47548643)
37. Gruber SA, Doshi MD, Cincotta E, et al. Preliminary experience with renal transplantation in HIV + recipients: Low acute rejection and infection rates. Transplantation 2008;86: 269-274.
38. Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7:2816-2620.
39. Kakuda TN, Schöller-Gyüre M, Hoetelmans RM. Pharma-cokinetic interactions between etravirine and non-anti-retroviral drugs. Clin Pharmacokinet 2011;50:25-39.
40. Crauwels HM, van Heeswijk RPG, Stevens T, et al. The effect of TMC278, a next generation NNRTI, on CYP3A activity in vivo. In: 10th International Workshop on Clinical Pharmacology of HIV Therapy [Abstract P28]. Amsterdam, The Netherlands: 2009.
41. Kontorinis N Dieterich DT. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 2003;23:173-182.
42. Bickel M, Anadol E, Vogel M, et al. Daily dosing of tacroli-mus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir. J Anti-microb Chemother 2010;65:999-1004.
43. Brinkman K, Huysmans F, Burger DM. Pharmacokinetic interaction between saquinavir and cyclosporine. Ann Intern Med 1998;129:914-915.
44. Frassetto LA, Tan-Tam C, Stock PG. Renal transplantation in patients with HIV. Nat Rev Nephrol 2009;5:582-589.
45. Guaraldi G, Cocchi S, Motta A, et al. Differential dose adjustments of immunosuppressants after resuming boosted versus unboosted HIV-protease inhibitors postliver transplant. Am J Transplant 2009;9:2429-2434.
46. Jain AK, Venkataramanan R, Fridell JA, et al. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: A case report. Liver Transpl 2002; 8:838-840. (Pubitemid 35012296)
47. Schvarcz R, Rudbeck G, Söderdahl G, Sta°hle L. Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). Transplantation 2000;69:2194-2195. (Pubitemid 30395060)
48. Sheikh AM, Wolf DC, Lebovics E, Goldberg R, Horowitz HW. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. Transplantation 1999;68:307-309. (Pubitemid 29360297)
49. Tsapepas DS, Webber AB, Aull MJ, Figueiro JM, Saal SD. Managing the atazanavir-tacrolimus drug interaction in a renal transplant recipient. Am J Health Syst Pharm 138-42.;68(2):138-42.
50. Pea F, Tavio M, Pavan F, Londero A, Bresadola V, Adani GL, Furlanut M, Viale P. Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fo-samprenavir in four HIV-infected liver transplant patients. Antivir Ther 2008;13:739-742.
51. Akhtar MZ, Patel N, Devaney A, et al. Simultaneous pancreas kidney transplantation in the HIV-positive patient. Transplant Proc 2011;43:3903-3904.
52. Barau C, Blouin P, Creput C, Taburet AM, Durrbach A, Furlan V. Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient. Fundam Clin Pharmacol 2009; 23:423-425.
53. Cousins D, Topping K, Lee V, Sweeney J, Lawton M. Successful tacrolimus treatment following renal transplant in a HIV-infected patient with raltegravir previously treated with a protease inhibitor based regimen. Drug Metab Drug Interactions 2011;26:139-141.
54. Guaraldi G, Cocchi S, Codeluppi M, et al. Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmpre-navir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. Transplant Proc 2006;38:1138-1140. (Pubitemid 43815874)
55. Hardy G, Stanke-Labesque F, Contamin C, et al. Protease inhibitors and diltiazem increase tacrolimus blood concentration in a patient with renal transplantation: A case report. Eur J Clin Pharmacol 2004;60:603-605. (Pubitemid 39517915)
56. Mertz D, Battegay M, Marzolini C, Mayr M. Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus. Am J Kidney Dis 2009;54:e1-4.
57. Morelle J, Goffin E, Wallemacq P, et al. Extended release tacrolimus and antiretroviral therapy in a renal transplant recipient: So extended! Transpl Int 2010;23:1065-1067.
58. Neff GW, Bonham A, Tzakis AG, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003;9: 239-247. (Pubitemid 36322325)
59. Schonder KS, Shullo MA, Okusanya O. Tacrolimus and lo-pinavir/ritonavir interaction in liver transplantation. Ann Pharmacother 2003;37:1793-1796. (Pubitemid 37466573)
60. Teicher E, Abbara C, Duclos-Vallée JC, et al. Enfuvirtide: A safe and effective antiretroviral agent for human immunodeficiency virus-infected patients shortly after liver transplantation. Liver Transplant 2009;15:1336-1342.
61. Vogel M, Voigt E, Michaelis HC, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl 2004;10:939-944. (Pubitemid 38979268)
62. Gregoor PJ, van Gelder T, van der Ende ME, Ijzermans JN, Weimar W. Cyclosporine and triple-drug treatment with human immunodeficiency virus protease inhibitors. Transplantation 1999;68:1210. (Pubitemid 29517716)
63. van Maarseveen EM, Crommelin HA, van den Broek MPH, Mudrikova T, van Zuilen AD. Pretransplantation curves of tacrolimus in HIV infected patients on ritonavir as predictor of posttransplantation exposure. (in press).
64. Dinavahi RV, Mehrotra A, Murphy BT, Huprikar S. Human immunodeficiency virus and renal transplantation. Kidney Int 2009;76:907-910.
65. Kageyama M, Namiki H, Fukushima H, et al. Effect of chronic administration of ritonavir on function of cyto-chrome P450 3A and P-glycoprotein in rats. Biol Pharm Bull 2005;28:130-137. (Pubitemid 40879797)
66. Katzenmaier S, Markert C, Riedel KD, Burhenne J, Haefeli WE, Mikus G. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy. Clin Pharmacol Ther 2011;90:666-673.
67. Scholten EM, Cremers SCLM, Shoemaker RC, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int 2005;67:2440-2447. (Pubitemid 41623408)
68. Nakamura Y, Takeuchi H, Okuyama K, et al. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under the trough level in tacrolimus and cyclo-sporine therapy. Transplant Proc 2005;37:1725-1727. (Pubitemid 40790810)
69. Tan Tam CC, Frassetto LA, Barin B, et al. The best single time point measurement correlations with AUC for cyclo-sporine (CSA) and tacrolimus (FK) in HIV-infected kidney and liver transplant recipients. American Society for Clinical Pharmacology and Therapeutics. Atlanta, GA: March 17-21, 2010.
70. Heredia A, Gilliam B, Latinovic O, Le N, Bamba D, Devico A, Melikyan GB, Gallo RC, Redfield RR. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother 2007;51:2489-2496. (Pubitemid 47047328)
71. Li J, Chen G, Ye P, et al. CCR5 blockade in combination with cyclosporine increased cardiac graft survival and generated alternatively activated macrophages in primates. J Immunol 2011;186:3753-3761.
72. Li J, Xia J, Zhang K, Xu L. Suppression of acute and chronic cardiac allograft rejection in mice by inhibition of chemokine receptor 5 in combination with cyclosporine A. J Surg Res 2009;157:81-90.
73. Heredia A, Latinovic O, Gallo RC, et al. Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proc Natl Acad Sci USA 2008;105:20476-20481.
74. Clinicaltrials.gov. www.clinicaltrials.gov/ct2/show/NCT009 48753?term=maraviroc+tacrolimus&rank=1(Last accessed March 3, 2012).
75. Abel S, Russell D, Whitlock LA, Ridgway CE, Muirhead GJ. Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorges-trel in healthy volunteers. Br J Clin Pharmacol. 2008;65 (Suppl 1):19-26. (Pubitemid 351366535)
76. Burger DM. Raltegravir: A review of its pharmacokinetics, pharmacology and clinical studies. Expert Opin Drug Metab Toxicol 2010;6:1151-1160.
77. Tricot L, Teicher E, Peytavin G, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009;9: 1946-1952.
78. Moreno A, Bárcena R, Quereda C, et al. Safe use of ralte-gravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation. AIDS. 2008;22:547-548. (Pubitemid 351317304)
79. Moreno A, Pérez-Elías MJ, Casado JL, et al. Raltegravir-based highly active antiretroviral therapy has beneficial effects on the renal function of human immunodeficiency virus-infected patients after solid organ transplantation. Liver Transpl 2010;16:530-532.
80. Lampiris HW. Elvitegravir: A once-daily, boosted, HIV-1 integrase inhibitor. Expert Rev Anti Infect Ther 2012;10: 13-20.
81. van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily do-lutegravir (S/GSK1349572) in combination therapy in anti-retroviral-naive adults with HIV: Planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012;12:111-118.
82. Waki K, Sugawara Y. Implications of integrase inhibitors for HIV-infected transplantation recipients: Raltegravir and dolutegravir (S/GSK 1349572). Biosci Trends 2011;5:189-191.